恩帕格利弗洛辛可以改善2型糖尿病患者的血管胰岛素敏感性和肌肉 perfusion
Linda A Jahn1, Lee M Hartline1, Thi Nguyen1
1Division of Endocrinology, Department of Medicine, University of Virginia, School of Medicine, Charlottesville, Virginia, United States.
American journal of physiology. Endocrinology and metabolism
|January 3, 2024
概括
糖共传输体2抑制剂 (SGLT2is) 通过增强血管胰岛素敏感性来改善心血管健康. 在2型糖尿病患者的empagliflozin治疗改善了血液动力学功能和微血管输液,有助于改善心脏和脏的结果.
科学领域:
- 心血管生理学心血管生理学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖共传输体2抑制剂 (SGLT2is) 在主要不良心血管事件,心力衰竭和结局方面显示出显著的益处.
- 这些临床改善的基础是精确的血管生理机制仍然不完全理解.
研究的目的:
- 调查SGLT2抑制剂治疗降低血管胰岛素抵抗并增强血动力学功能的假设.
- 阐明empagliflozin对2型糖尿病患者血管硬,内皮功能,动脉压力和微血管输液的影响.
主要方法:
- 一项为期12周的开放性研究,涉及11名2型糖尿病患者,接受Empagliflozin (10 mg/天) 治疗.
- 血管评估包括硬度,内皮功能,动脉压和微血管输液在基线和12周的euglycemic高胰岛素血压之前和之后被测量.
主要成果:
- 恩帕格利弗洛辛治疗显著改善了内皮功能和胰岛素介导的骨和心脏肌肉中的微血管输液.
- 在使用empagliflozin之后,胰岛素输注导致了外周和中心大动脉压力的显著降低,并改善了血管反应.
结论:
- 恩帕格利弗洛辛增强了胰岛素的血管作用,这表明它对心脏和脏的益处的关键机制.
- 这些发现强调了血管胰岛素敏感性改善在调解与SGLT2抑制剂治疗相关的积极临床结果中的作用.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K


